CureVac’s Covid Vaccine Performed Badly in Trial, In Part Due to Variants

A preliminary analysis estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent. “This is pretty devastating for them,” one expert said.

View original article
Contributor: Carl Zimmer